First Manhattan’s Ascendis Pharma A/S ASND Stock Holding History

First Manhattan’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-69,849	Closed	-$9.19M	–	1581
2021 Q2	$9.19M	Sell	69,849 -9,659	-12%	-$1.29M	0.03%	169
2021 Q1	$10.2M	Sell	79,508 -14,092	-15%	-$2.14M	0.04%	155
2020 Q4	$15.6M	Hold	93,600	–	–	0.07%	120
2020 Q3	$14.4M	Hold	93,600	–	–	0.07%	120
2020 Q2	$13.8M	Sell	93,600 -2,600	-3%	-$357K	0.08%	116
2020 Q1	$10.8M	Buy	96,200 +1,700	+2%	+$221K	0.07%	137
2019 Q4	$13.1M	Buy	94,500 +22,000	+30%	+$2.44M	0.07%	142
2019 Q3	$6.98M	Sell	72,500 -2,500	-3%	-$279K	0.04%	200
2019 Q2	$8.64M	Hold	75,000	–	–	0.05%	179
2019 Q1	$8.83M	Sell	75,000 -168,306	-69%	-$14.7M	0.05%	173
2018 Q4	$15.2M	Sell	243,306 -29,931	-11%	-$1.88M	0.09%	122
2018 Q3	$19.4M	Sell	273,237 -82,111	-23%	-$5.65M	0.1%	125
2018 Q2	$23.6M	Hold	355,348	–	–	0.14%	112
2018 Q1	$23.2M	Hold	355,348	–	–	0.13%	113
2017 Q4	$14.2M	Hold	355,348	–	–	0.08%	160
2017 Q3	$12.9M	Buy	+355,348	New	+$10.2M	0.07%	164

Other funds holding ASND

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

First Manhattan's ASND Position: Q3 2021 in Review

First Manhattan sold out of Ascendis Pharma A/S (ASND) in Q3 2021, closing a stake of 69,849 shares — an estimated $9.19M sold.

First Manhattan first reported a position in ASND in Q3 2017 and held it in 16 quarters. The position peaked at $23.6M in Q2 2018. 166 funds tracked by Wall St. Rank hold ASND as of Q3 2021.

First Manhattan reported no remaining Ascendis Pharma A/S position as of Q3 2021 after selling out during the quarter.
First Manhattan sold 69,849 Ascendis Pharma A/S shares in Q3 2021, an estimated $9.19M.
First Manhattan first reported a position in Ascendis Pharma A/S in Q3 2017 and held it in 16 quarters.
First Manhattan's Ascendis Pharma A/S position peaked at $23.6M in Q2 2018.
166 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q3 2021.

Based on First Manhattan's 13F filing for Q3 2021, filed 15 Nov 2021.